Jonathan Hopper
Chief Tech/Sci/R&D Officer bei VERICEL CORPORATION
Vermögen: 3 Mio $ am 31.03.2024
Profil
Jonathan Mark Hopper is currently the Chief Medical Officer at Vericel Corp.
He previously worked as the Vice President-Global Medical Director at Stryker Corp from 2010 to 2014, the Chief Medical Officer at Osiris Therapeutics, Inc. from 2014 to 2016, and the Medical Director at Ferring Pharmaceuticals, Inc. in 2017-2018.
He also served as the Senior Medical Officer at the United Kingdom Department of Health & Social Care and as the Vice President-Medical Affairs at ConvaTec, Inc. from 2006 to 2010.
Dr. Hopper holds an MBA from Keele University and an undergraduate degree from the University of Birmingham Medical School.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
VERICEL CORPORATION
0,12% | 08.03.2024 | 58 110 ( 0,12% ) | 3 Mio $ | 31.03.2024 |
Aktive Positionen von Jonathan Hopper
| Unternehmen | Position | Beginn |
|---|---|---|
| VERICEL CORPORATION | Chief Tech/Sci/R&D Officer | 20.08.2018 |
Ehemalige bekannte Positionen von Jonathan Hopper
| Unternehmen | Position | Ende |
|---|---|---|
Ferring Pharmaceuticals, Inc.
 Ferring Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Ferring Pharmaceuticals, Inc. develops and markets fertility and endocrinology products. Its products include Bravelle, Repronex, Novarel, Acthrel and Desmopressin Acetate. The company's products are used in treatment of osteoarthritis, prostate cancer, and other infertility related diseases. Ferring Pharmaceuticals was founded in 1951 and is headquartered in Parsippany, NJ. | Chief Tech/Sci/R&D Officer | 01.08.2018 |
| OSIRIS THERAPEUTICS, INC. | Chief Tech/Sci/R&D Officer | 12.04.2016 |
| STRYKER CORPORATION | Chief Tech/Sci/R&D Officer | 01.11.2014 |
ConvaTec, Inc.
 ConvaTec, Inc. Medical SpecialtiesHealth Technology ConvaTec, Inc. engages in the manufacture of medical products and technologies focused on therapies for the management of chronic conditions. It specializes in the wound care, ostomy care, continence and critical care, and infusion devices. The company was founded in 1978 and is headquartered in Bridgewater, NJ. | Chief Tech/Sci/R&D Officer | 01.08.2010 |
| United Kingdom Department of Health & Social Care | Corporate Officer/Principal | - |
Ausbildung von Jonathan Hopper
| Keele University | Masters Business Admin |
| University of Birmingham Medical School | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 2 |
|---|---|
| STRYKER CORPORATION | Health Technology |
| VERICEL CORPORATION | Health Technology |
| Private Unternehmen | 4 |
|---|---|
Osiris Therapeutics, Inc.
 Osiris Therapeutics, Inc. BiotechnologyHealth Technology Osiris Therapeutics, Inc. engages in the research, development, manufacture, and commercialization of regenerative medicine products. Its biosurgery business focuses on using unique tissue preservation technologies to develop viable human tissue products designed to improve wound closure and surgical outcomes for patients and physicians over standard of care alone. The company was founded by Peter A. Friedli and James S. Burns on December 23, 1992 and is headquartered in Columbia, MD. | Health Technology |
| United Kingdom Department of Health & Social Care | Government |
ConvaTec, Inc.
ConvaTec, Inc. Medical SpecialtiesHealth Technology ConvaTec, Inc. engages in the manufacture of medical products and technologies focused on therapies for the management of chronic conditions. It specializes in the wound care, ostomy care, continence and critical care, and infusion devices. The company was founded in 1978 and is headquartered in Bridgewater, NJ. | Health Technology |
Ferring Pharmaceuticals, Inc.
Ferring Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Ferring Pharmaceuticals, Inc. develops and markets fertility and endocrinology products. Its products include Bravelle, Repronex, Novarel, Acthrel and Desmopressin Acetate. The company's products are used in treatment of osteoarthritis, prostate cancer, and other infertility related diseases. Ferring Pharmaceuticals was founded in 1951 and is headquartered in Parsippany, NJ. | Health Technology |
